Filtered By:
Management: Economics

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 211 results found since Jan 2013.

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm
CONCLUSIONS: Biologics are emerging as an important option in the management of patients with CRSwNP. While more data is required to fully inform indications, treatment selection, and health economics related to their use, biologics may offer robust symptom relief to patients who have failed other interventions.PMID:36848277 | DOI:10.1177/19458924221147758
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Neal R Godse Anjeni Keswani Andrew P Lane Stella E Lee Raj Sindwani Source Type: research

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm
CONCLUSIONS: Biologics are emerging as an important option in the management of patients with CRSwNP. While more data is required to fully inform indications, treatment selection, and health economics related to their use, biologics may offer robust symptom relief to patients who have failed other interventions.PMID:36848277 | DOI:10.1177/19458924221147758
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Neal R Godse Anjeni Keswani Andrew P Lane Stella E Lee Raj Sindwani Source Type: research

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm
CONCLUSIONS: Biologics are emerging as an important option in the management of patients with CRSwNP. While more data is required to fully inform indications, treatment selection, and health economics related to their use, biologics may offer robust symptom relief to patients who have failed other interventions.PMID:36848277 | DOI:10.1177/19458924221147758
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Neal R Godse Anjeni Keswani Andrew P Lane Stella E Lee Raj Sindwani Source Type: research

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm
CONCLUSIONS: Biologics are emerging as an important option in the management of patients with CRSwNP. While more data is required to fully inform indications, treatment selection, and health economics related to their use, biologics may offer robust symptom relief to patients who have failed other interventions.PMID:36848277 | DOI:10.1177/19458924221147758
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Neal R Godse Anjeni Keswani Andrew P Lane Stella E Lee Raj Sindwani Source Type: research

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm
CONCLUSIONS: Biologics are emerging as an important option in the management of patients with CRSwNP. While more data is required to fully inform indications, treatment selection, and health economics related to their use, biologics may offer robust symptom relief to patients who have failed other interventions.PMID:36848277 | DOI:10.1177/19458924221147758
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Neal R Godse Anjeni Keswani Andrew P Lane Stella E Lee Raj Sindwani Source Type: research

Economics of Medical and Surgical Management of Chronic Rhinosinusitis with Nasal Polyps: A Contemporary Review
CONCLUSION: CRSwNP is a chronic condition with high recurrence rates making it a challenge to manage over time. Current research suggests that FESS is more cost-effective than medical management, including use of newer biologics. Further investigation into both direct and indirect costs associated with medical management is warranted to perform accurate cost-effectiveness analyses and allow for the best allocation of limited healthcare resources.PMID:36848274 | DOI:10.1177/19458924221147501
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Nikita Chapurin Sofia Khan Jorge Gutierrez Zachary M Soler Source Type: research

Follow-up of penicillin allergy labels 1 year after successful penicillin delabeling
Penicillin allergy delabeling confers many benefits, including reduced patient morbidity and mortality and improved health economics. Reports suggest that both patients and clinicians often remain hesitant to take and prescribe penicillins, respectively, after penicillin delabeling. However, follow-up of an individual's penicillin allergy label and incorporation of this into relevant health care records after delabeling have not been well studied in the Australian population.
Source: Annals of Allergy, Asthma and Immunology - September 15, 2022 Category: Allergy & Immunology Authors: Trisha Pinto, Jamma Li, Therese Boyle, Reina Zaragoza, Suran L. Fernando Tags: Original Article Source Type: research

The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients
CONCLUSIONS: Omalizumab could provide substantial benefits in terms of paid and unpaid work activities in patients with severe and most severe JCP. Our results also highlight the importance of considering unpaid work in estimating productivity costs due to poor health.PMID:35072591 | DOI:10.1080/13696998.2022.2033051
Source: Journal of Medical Economics - January 24, 2022 Category: Health Management Authors: M M üller A Igarashi K Hashiguchi M Kappel F Paolini H Yoshisue M Funakubo H Sharma M Okano Source Type: research

Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics
SummaryBiologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short-term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost-effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various tre...
Source: International Forum of Allergy and Rhinology - July 12, 2021 Category: Allergy & Immunology Authors: Lauren T. Roland, Alan Regenberg, Amber U. Luong, Sarah K. Wise, Elina Toskala, Kent K. Lam, Joshua M. Levy, Christine B. Franzese, Kristine Smith, Jean Kim Tags: VIEWPOINT Source Type: research

Mechanics and Economics of a Negative Pressure Pulmonary Function Lab in the COVID-19 Era
Publication date: July 2021Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 9, Issue 7Author(s): Timothy C. Olsen, Siu Lam Koo, Robert A. Promisloff, Michael Bohlens, Anthony M. Szema
Source: The Journal of Allergy and Clinical Immunology: In Practice - July 7, 2021 Category: Allergy & Immunology Source Type: research